Increased endothelin expression in a rat cardiac allograft model of chronic vascular rejection

Transplantation
R D ForbesR D Guttmann

Abstract

Endothelins (ET) are potent vasoconstrictors that are directly mitogenic for vascular smooth muscle cells and fibroblasts. It is possible that the vasoconstrictor and mitogenic effects of ET could play a significant role in the vascular remodeling process that occurs in chronic vascular rejection (CVR). We have previously shown that cardiac allografts in the indefinitely surviving major histocompatibility complex identical WF.1L (RT1(1)) to Lewis (LEW) (RT1(1)) inbred rat strain combination provide a highly reproducible model of progressive CVR. The objective of this investigation was to measure endothelin-1 ventricular content of WF.1L-LEW cardiac allografts and to determine the immunohistochemical patterns of ET cellular reactivity at well defined posttransplant time periods. Data were compared with those obtained in similar studies of LEW-LEW syngeneic: heart grafts as well as all recipients' own hearts. The ventricular ET-1 content of the WF.1L cardiac allografts was markedly higher (4.3-, 7.0-, and 4.8-fold at 20, 40, and 60 days, respectively) than in corresponding recipients' hearts. Also, the increase in ventricular ET-1 levels as compared with the recipients' hearts rose significantly only in the allograft group. No co...Continue Reading

References

Dec 1, 1990·The Journal of Experimental Medicine·H EhrenreichA S Fauci
Jul 1, 1991·The Journal of Clinical Investigation·T E Bunchman, C A Brookshire
Jul 5, 1990·The New England Journal of Medicine·J R VaneR M Botting
May 16, 1990·Biochemical and Biophysical Research Communications·T J ResinkF R Bühler
Sep 29, 1989·Biochemical and Biophysical Research Communications·W G NaylerP L Mottram
Nov 15, 1989·Biochemical and Biophysical Research Communications·J J LiuW G Nayler
Feb 1, 1989·Journal of Applied Physiology·H L LipptonA L Hyman
Jun 15, 1989·Biochemical and Biophysical Research Communications·P Cernacek, D J Stewart
Jan 1, 1984·Immunological Reviews·R D Forbes, R D Guttmann
Jan 1, 1993·Journal of Cardiovascular Pharmacology·S A Douglas, E H Ohlstein
Dec 11, 1993·Lancet·D J Webb, W G Haynes
May 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·H TanakaP Libby
Dec 1, 1993·Cardiovascular Research·E GuardaK T Weber
Mar 31, 1993·Biochemical and Biophysical Research Communications·J A WinklesP Libby

❮ Previous
Next ❯

Citations

Feb 1, 1997·Transplantation Proceedings·S X ZhengR D Guttmann
Apr 3, 2002·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Atsushi YamaguchiRobert C Robbins
Apr 12, 2000·Kidney International·A Benigni
Jun 17, 2003·Molecular Biology of the Cell·Rong ShaoDon C Rockey
Apr 15, 1997·Transplantation·A T ArmstrongC G Orosz
Jul 4, 2003·Canadian Journal of Physiology and Pharmacology·Nicolas Bousette, Adel Giaid
Sep 9, 1998·American Journal of Respiratory Cell and Molecular Biology·Y GuoS N Hussain
May 1, 1997·The American Journal of the Medical Sciences·R D GuttmannS X Zheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.